We focused on reporting the results of stage A and B patients because most of the patients in advanced BCLC stages (stage C and D) received only palliative care and no active treatment at that time. Furthermore, patients with advanced BCLC stages typically suffer from complications of terminal liver cirrhosis which has a considerable influence on survival. To minimize the influence of the underlying liver disease and to focus on the impact of tumour treatment
on survival, patients with advanced BCLC stages were excluded. MELD scores within the BCLC stages A and B, respectively and various treatment modalities were not statistically significant learn more when tested allowing for multiple comparisons (p = 0.07). The demographic data and clinical characteristics are given in Table 1. Liver cirrhosis was diagnosed either by histology or by the typical combination of laboratory tests, clinical and gastroscopic findings and typical signs of liver cirrhosis in CT or ultrasound. Diagnosis of hepatocellular carcinoma was done according to the criteria of EASL [15] and AASLD [16]. Histologic confirmation was performed in 31 of 40 (77.5%) patients in BCLC stage A and 50 of 55 (90.9%) patients with BCLC stage B. Overall, hepatocellular
carcinoma was histologically confirmed GSK1210151A order in 85.3% of our patients. Table 1 Characteristics of patients with HCC according to treatment modalities the Sandostatin LAR TACE multimodal therapy palliative care BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B number 11 14 5 9 7 10 17 22 Sex male 6 10 4 8 7 9 14 16 female 5 4 1 1 0 1 3 6 liver cirrhosis no 0 0 0 2 1 0 2 2 yes 11 14 5 7 6 10 15 20 Child-Pugh-classification Child A 9 12 1 3 5 8 7 7 Child
B 2 2 4 4 1 2 8 13 Child C 0 0 0 0 0 0 0 0 MELD (median/range) 7.33 (0.27-15.98) 7.61 (0.16-15.0) 14.60 (11.13-17.35) 11.46 (6.68-16.90) 11.56 (6.78-49.26) 8.98 (7.15-16.01) 12.31 (4.66-58.20) 13.20 (1.53-49.82) Etiology Alcoholism 5 8 2 4 5 3 8 8 chronic hepatitis B 1 0 0 0 1 0 2 0 chronic hepatitis C 4 4 3 2 1 7 5 7 others 1 2 0 3 0 0 2 6 Age (median/range) 66.5 (53.7-80.5) 68.7 (49.4-73.4) 64.9 (63.6-69.2) 68.4 (48.4-78.4) 50.5 (47.4-64.6) 69.9 (61.2-76.9) 68.5 (43.1-81.2) 62.5 (44.8-73.4) Treatment modalities Long-acting Octreotide [Sandostatin LAR] 30 mg long-acting octreotide (Sandostatin-LAR™, Novartis, Basel, MK-0518 Switzerland) was given i.m. once a month until death. This therapy was given within the context of an unpublished study to compare the clinical outcome of additional percutaneous ethanol instillation (PEI) against no further treatment in patients with HCC, all receiving hormonal treatment with long-acting octreotide. All patients (n = 25) who received only treatment with long-acting octreotide were included in this retrospective comperative study.